Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Osimertinib confers potent binding affinity to EGFR Kinase Domain Duplication.

Jin R, Li J, Jin Z, Lu Y, Shao YW, Li W, Zhao G, Xia Y.

Int J Cancer. 2019 Aug 8. doi: 10.1002/ijc.32617. [Epub ahead of print] No abstract available.

PMID:
31393596
2.

Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.

Shen B, Wu F, Ye J, Liang R, Wang R, Yu R, Wu X, Shao YW, Feng J.

Future Oncol. 2019 Aug;15(22):2585-2593. doi: 10.2217/fon-2019-0140. Epub 2019 Jul 24.

PMID:
31339066
3.

Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.

Yang Z, Yang J, Chen Y, Shao YW, Wang X.

Target Oncol. 2019 Aug;14(4):369-374. doi: 10.1007/s11523-019-00652-6.

PMID:
31301016
4.

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.

Xu J, Bao H, Wu X, Wang X, Shao YW, Sun T.

Oncol Lett. 2019 Jul;18(1):449-455. doi: 10.3892/ol.2019.10287. Epub 2019 Apr 30.

5.

Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).

Wang H, Ou Q, Li D, Qin T, Bao H, Hou X, Wang K, Wang F, Deng Q, Liang J, Zheng W, Wu X, Wang X, Shao YW, Mou Y, Chen L.

Cancer. 2019 Jul 9. doi: 10.1002/cncr.32372. [Epub ahead of print]

PMID:
31287555
6.

Dewatering of sewage sludge via thermal hydrolysis with ammonia-treated Fenton iron sludge as skeleton material.

Xu ZX, Song H, Deng XQ, Zhang YY, Xue-Qin M, Tong SQ, He ZX, Wang Q, Shao YW, Hu X.

J Hazard Mater. 2019 Jun 22;379:120810. doi: 10.1016/j.jhazmat.2019.120810. [Epub ahead of print]

PMID:
31255849
7.

Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.

Ge J, Yao B, Huang J, Wu X, Bao H, Ou Q, Shao YW, Chen J.

BMC Cancer. 2019 Jun 17;19(1):592. doi: 10.1186/s12885-019-5780-4.

8.

Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report.

Gu Y, Zhu X, Cao B, Wu X, Tong X, Shao YW, Liang L.

Oncol Lett. 2019 Jun;17(6):5219-5223. doi: 10.3892/ol.2019.10196. Epub 2019 Mar 28.

9.

Nkx2-4 Mutation Confers Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Sarcomatoid Carcinoma.

Xia L, Shao YW, Xia Y.

J Thorac Oncol. 2019 Jun;14(6):e125-e126. doi: 10.1016/j.jtho.2019.01.027. No abstract available.

PMID:
31122564
10.

Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma.

Ye M, Lv J, Xu G, Wang W, Jing Y, Sun A, Lu Z, Wu X, Liu Y, Shao YW, Liu F, Tao F.

J Int Med Res. 2019 Jun;47(6):2768-2777. doi: 10.1177/0300060519847796. Epub 2019 May 20.

11.

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.

Fang W, Ma Y, Yin JC, Hong S, Zhou H, Wang A, Wang F, Bao H, Wu X, Yang Y, Huang Y, Zhao H, Shao YW, Zhang L.

Clin Cancer Res. 2019 Aug 15;25(16):5015-5026. doi: 10.1158/1078-0432.CCR-19-0585. Epub 2019 May 13.

PMID:
31085721
12.

Melamine Foam-Supported Form-Stable Phase Change Materials with Simultaneous Thermal Energy Storage and Shape Memory Properties for Thermal Management of Electronic Devices.

Jing JH, Wu HY, Shao YW, Qi XD, Yang JH, Wang Y.

ACS Appl Mater Interfaces. 2019 May 29;11(21):19252-19259. doi: 10.1021/acsami.9b06198. Epub 2019 May 16.

PMID:
31070355
13.

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.

Ding M, Deng L, Yu R, Lu D, Bai Y, Wu X, Shao YW, Yang Y.

Clin Lung Cancer. 2019 May;20(3):e229-e232. doi: 10.1016/j.cllc.2019.02.014. Epub 2019 Feb 27. No abstract available.

PMID:
30948231
14.

Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing.

Zhao ZR, Lin YB, Ng CSH, Zhang R, Wu X, Ou Q, Chen W, Zhou WJ, Lin YB, Su XD, Shao YW, Long H.

Oncologist. 2019 Mar 14. pii: theoncologist.2018-0567. doi: 10.1634/theoncologist.2018-0567. [Epub ahead of print]

PMID:
30872465
15.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

PMID:
30735634
16.

Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA.

Sun P, Chen C, Xia Y, Wang Y, Liu PP, Bi XW, Shao YW, Ou QX, Wu X, Yang H, Nie M, Zhang XW, Li ZM, Jiang WQ.

J Cancer. 2019 Jan 1;10(2):323-331. doi: 10.7150/jca.27615. eCollection 2019.

17.

Hydrothermal liquefaction of cellulose in ammonia/water.

Xu ZX, Cheng JH, He ZX, Wang Q, Shao YW, Hu X.

Bioresour Technol. 2019 Apr;278:311-317. doi: 10.1016/j.biortech.2019.01.061. Epub 2019 Jan 15.

PMID:
30711839
18.

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

Wang X, Zhou L, Yin JC, Wu X, Shao YW, Gao B.

J Thorac Oncol. 2019 May;14(5):e85-e88. doi: 10.1016/j.jtho.2019.01.015. Epub 2019 Jan 31. No abstract available.

PMID:
30711650
19.

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.

Wang B, Gao Y, Huang Y, Ou Q, Fang T, Tang C, Wu X, Shao YW.

Clin Lung Cancer. 2019 May;20(3):e233-e237. doi: 10.1016/j.cllc.2018.12.017. Epub 2018 Dec 31. No abstract available.

PMID:
30691963
20.

Responsiveness to Full-Dose Afatinib in a Patient With Lung Adenocarcinoma Harboring EGFR S768I and V769L Mutations.

Zhang H, Shao YW, Xia Y.

J Thorac Oncol. 2019 Feb;14(2):e25-e27. doi: 10.1016/j.jtho.2018.10.165. No abstract available.

PMID:
30683293
21.

Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.

Yu Y, Ou Q, Wu X, Bao H, Ding Y, Shao YW, Lu S.

Lung Cancer. 2019 Jan;127:19-24. doi: 10.1016/j.lungcan.2018.11.024. Epub 2018 Nov 22.

PMID:
30642546
22.

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.

Lu S, Yu Y, Li Z, Yu R, Wu X, Bao H, Ding Y, Shao YW, Jian H.

J Thorac Oncol. 2019 Apr;14(4):732-736. doi: 10.1016/j.jtho.2018.12.006. Epub 2019 Jan 2.

PMID:
30610926
23.

High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations.

Hong T, Yan Y, Li J, Radovanovic I, Ma X, Shao YW, Yu J, Ma Y, Zhang P, Ling F, Huang S, Zhang H, Wang Y.

Brain. 2019 Jan 1;142(1):23-34. doi: 10.1093/brain/awy307.

PMID:
30544177
24.

Genomic profiling of synchronous triple primary tumors of the lung, thyroid and kidney in a young female patient: A case report.

Peng L, Zeng Z, Teng X, Chen Z, Lin L, Bao H, Shao YW, Wang Y, Dong Y, Zhao Q.

Oncol Lett. 2018 Nov;16(5):6089-6094. doi: 10.3892/ol.2018.9334. Epub 2018 Aug 20.

25.

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.

Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW, Xu RH.

Gut. 2019 Jul;68(7):1152-1161. doi: 10.1136/gutjnl-2018-316522. Epub 2018 Sep 29.

PMID:
30269082
26.

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.

Jin Y, Shi X, Zhao J, He Q, Chen M, Yan J, Ou Q, Wu X, Shao YW, Yu X.

Lung Cancer. 2018 Oct;124:110-116. doi: 10.1016/j.lungcan.2018.07.039. Epub 2018 Jul 29.

PMID:
30268447
27.

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.

Wang J, Li X, Xue X, Ou Q, Wu X, Liang Y, Wang X, You M, Shao YW, Zhang Z, Zhang S.

Int J Cancer. 2019 Jun 1;144(11):2677-2682. doi: 10.1002/ijc.31895. Epub 2018 Dec 16.

28.

Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer.

Guo LC, Zhu WD, Ma XY, Ni H, Zhong EJ, Shao YW, Yu J, Gu DM, Ji SD, Xu HD, Ji C, Yang JM, Zhang Y.

Cancer Biol Ther. 2019;20(3):240-246. doi: 10.1080/15384047.2018.1523856. Epub 2018 Sep 25.

PMID:
30252567
29.

Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions.

Wen L, Xu Y, Yao L, Wang N, Wang Q, Liu T, Pan J, Cen J, Zhou H, Miao M, Shao YW, Wang X, Wang X, Ruan C, Wu D, Chen S.

Haematologica. 2019 May;104(5):e195-e199. doi: 10.3324/haematol.2018.205369. Epub 2018 Sep 20. No abstract available.

30.

Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms.

Xu Y, Tong X, Yan J, Wu X, Shao YW, Fan Y.

Transl Oncol. 2018 Dec;11(6):1364-1369. doi: 10.1016/j.tranon.2018.08.010. Epub 2018 Sep 7.

31.

Fluorescence-Based Nano-Oxygen Particles for Spatiometric Monitoring of Cell Physiological Conditions.

Koduri MP, S Goudar V, Shao YW, Hunt JA, Henstock JR, Curran J, Tseng FG.

ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30163-30171. doi: 10.1021/acsami.8b10715. Epub 2018 Aug 31.

PMID:
30118196
32.

Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma.

Shao YW, Wood GA, Lu J, Tang QL, Liu J, Molyneux S, Chen Y, Fang H, Adissu H, McKee T, Waterhouse P, Khokha R.

Oncogene. 2019 Jan;38(2):291-298. doi: 10.1038/s41388-018-0444-4. Epub 2018 Aug 9.

PMID:
30093633
33.

CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.

Zhang M, Wang Q, Ding Y, Wang G, Chu Y, He X, Wu X, Shao YW, Lu K.

J Thorac Oncol. 2018 Nov;13(11):1792-1797. doi: 10.1016/j.jtho.2018.07.008. Epub 2018 Aug 7.

PMID:
30010043
34.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

Kang J, Chen HJ, Zhang XC, Su J, Zhou Q, Tu HY, Wang Z, Wang BC, Zhong WZ, Yang XN, Chen ZH, Ding Y, Wu X, Wang M, Fu JG, Yang Z, Zhang X, Shao YW, Wu YL, Yang JJ.

Thorac Cancer. 2018 Sep;9(9):1093-1103. doi: 10.1111/1759-7714.12791. Epub 2018 Jul 6.

35.

Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.

Yang M, Tong X, Xu X, Zheng E, Ni J, Li J, Yan J, Shao YW, Zhao G.

Lung Cancer. 2018 Jul;121:1-4. doi: 10.1016/j.lungcan.2018.04.006. Epub 2018 Apr 5.

PMID:
29858019
36.

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

Mei Z, Shao YW, Lin P, Cai X, Wang B, Ding Y, Ma X, Wu X, Xia Y, Zhu D, Shu Y, Fu Z, Gu Y.

BMC Cancer. 2018 Apr 27;18(1):479. doi: 10.1186/s12885-018-4298-5.

37.

Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.

Liu Y, Li Y, Ou Q, Wu X, Wang X, Shao YW, Ying J.

Lung Cancer. 2018 Apr;118:1-5. doi: 10.1016/j.lungcan.2018.01.015. Epub 2018 Jan 31.

PMID:
29571986
38.

Genetic and clonal dissection of osteosarcoma progression and lung metastasis.

Xu H, Zhu X, Bao H, Wh Shek T, Huang Z, Wang Y, Wu X, Wu Y, Chang Z, Wu S, Tang Q, Zhang H, Han A, Mc Cheung K, Zou C, Yau R, Ho WY, Huang G, Batalha S, Lu J, Song G, Kang Y, Shao YW, Lam YL, Shen J, Wang J.

Int J Cancer. 2018 Sep 1;143(5):1134-1142. doi: 10.1002/ijc.31389. Epub 2018 May 13.

PMID:
29569716
39.

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C.

Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5.

40.

Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.

Lu H, Yang S, Zhu H, Tong X, Xie F, Qin J, Han N, Wu X, Fan Y, Shao YW, Mao W.

BMC Cancer. 2018 Mar 5;18(1):251. doi: 10.1186/s12885-018-4159-2.

41.

GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.

Jiang J, Wu X, Tong X, Wei W, Chen A, Wang X, Shao YW, Huang J.

Lung Cancer. 2018 Jan;115:5-11. doi: 10.1016/j.lungcan.2017.10.011. Epub 2017 Oct 27.

PMID:
29290262
42.

JAK2 variations and functions in lung adenocarcinoma.

Xu Y, Jin J, Xu J, Shao YW, Fan Y.

Tumour Biol. 2017 Jun;39(6):1010428317711140. doi: 10.1177/1010428317711140.

PMID:
28639892
43.

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.

Du J, Wu X, Tong X, Wang X, Wei J, Yang Y, Chang Z, Mao Y, Shao YW, Liu B.

Oncotarget. 2017 Apr 18;8(16):26281-26287. doi: 10.18632/oncotarget.15457.

44.

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.

Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao Y, Chen X, Sun J, Wang Z, Hong Z, Zhu L, Zhu C, Chen J, Liang Y, Shao H, Shao YW.

Sci Rep. 2017 Apr 3;7(1):583. doi: 10.1038/s41598-017-00520-1.

45.

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

Chen K, Zhou F, Shen W, Jiang T, Wu X, Tong X, Shao YW, Qin S, Zhou C.

J Thorac Oncol. 2017 Jun;12(6):e65-e68. doi: 10.1016/j.jtho.2016.12.024. Epub 2017 Jan 16. No abstract available.

46.

Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns.

Ma X, Zhu L, Wu X, Bao H, Wang X, Chang Z, Shao YW, Wang Z.

PLoS One. 2017 Jan 3;12(1):e0169231. doi: 10.1371/journal.pone.0169231. eCollection 2017.

47.

Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.

Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas C, Hess FM, Ohtsuka T, Okada Y, Ailles L, Ludwig A, Wrana JL, Kislinger T, Khokha R.

Nat Cell Biol. 2014 Sep;16(9):889-901. doi: 10.1038/ncb3021. Epub 2014 Aug 24.

PMID:
25150980
48.

Human somatic cell mutagenesis creates genetically tractable sarcomas.

Molyneux SD, Waterhouse PD, Shelton D, Shao YW, Watling CM, Tang QL, Harris IS, Dickson BC, Tharmapalan P, Sandve GK, Zhang X, Bailey SD, Berman H, Wunder JS, Izsvák Z, Lupien M, Mak TW, Khokha R.

Nat Genet. 2014 Sep;46(9):964-72. doi: 10.1038/ng.3065. Epub 2014 Aug 17. Erratum in: Nat Genet. 2014 Dec;46(12):1372. Iszvak, Zsuzsanna [corrected to Izsvák, Zsuzsanna.

PMID:
25129143
49.

Acid-induced hyperalgesia and anxio-depressive comorbidity in rats.

Liu YT, Shao YW, Yen CT, Shaw FZ.

Physiol Behav. 2014 May 28;131:105-10. doi: 10.1016/j.physbeh.2014.03.030. Epub 2014 Apr 12.

PMID:
24726391
50.

Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis.

Murthy A, Shao YW, Defamie V, Wedeles C, Smookler D, Khokha R.

J Immunol. 2012 Mar 15;188(6):2876-83. doi: 10.4049/jimmunol.1102199. Epub 2012 Feb 8.

Supplemental Content

Support Center